Pacific Biosciences
PACB
106 hedge funds and large institutions have $406M invested in Pacific Biosciences in 2017 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 22 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
69% more capital invested
Capital invested by funds: $240M → $406M (+$166M)
2.72% more ownership
Funds ownership: 68.2% → 70.92% (+2.7%)
3% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 33
8% less funds holding
Funds holding: 115 → 106 (-9)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
94% less call options, than puts
Call options by funds: $244K | Put options by funds: $4.09M
Top Buyers
| 1 |
BlackRock
New York
|
+$38.5M |
| 2 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
+$24.2M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$11.9M |
| 4 |
Credit Agricole
Montrouge Cedex,
France
|
+$10.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.26M |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$28M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.84M |
| 3 |
Millennium Management
New York
|
-$4.55M |
| 4 |
LCS
Levin Capital Strategies
New York
|
-$3.97M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.88M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Simplex Trading
Chicago,
Illinois
| – | -$12.3K | -2,516 | Closed |
|
127
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$6K | -1,700 | Closed |
|
|
MAM
128
Meeder Asset Management
Dublin,
Ohio
| – | +$406 | +83 | New |
|
PACB Hedge Fund Activity: Q1 2017 in Review
106 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2017, worth a combined $406M — up 69% from $240M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PACB and 19 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 32 added.
The largest buyer was BlackRock, adding an estimated $38.5M. The largest seller was UBS Group, cutting an estimated $28M.
- 106 institutional investors held Pacific Biosciences (PACB) as of Q1 2017, down from 115 in Q4 2016.
- Funds reported $406M of Pacific Biosciences stock for Q1 2017, up 69% quarter-over-quarter.
- 19 funds opened new Pacific Biosciences positions in Q1 2017 and 22 closed out, a net change of -3 holders.
- The largest Pacific Biosciences buyer in Q1 2017 was BlackRock, an estimated $38.5M added.
- The largest Pacific Biosciences seller in Q1 2017 was UBS Group, an estimated $28M sold.
Based on aggregated 13F filings for Q1 2017.